Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Most Cited Paper
in Cancer-related Molecular Pathways
18 Months Post-Publication
Class of 2026
“Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
abemaciclib · fulvestrant · CDK4/6 inhibitor · endocrine therapy · hormone receptor-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · progression-free survival · aromatase inhibitor · ESR1 mutations · PIK3CA mutation · Overall response rate · blinded independent central review · postMONARCH trial · treatment rechallenge · acquired resistance
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459